Medicine
Venlafaxine 225 mg extended-release tablet
Venlafaxine 225 mg extended-release tablet is a generic prescription medicine for oral use, made by 11 labelers, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20° to 25°C (68° to 77°F), excursions permitted between 15° to 30°C…
Key facts
- Active ingredient (INN)
- Venlafaxine
- Brand
- Sold under the generic name
- Strength
- 225 mg
- Dosage form
- Extended-release tablet
- Route
- Oral
- Packs
- 100 tablets, 30 tablets, 90 tablets and 27 more
- Manufacturers
- Sun Pharmaceutical IndustriesIndiaZydus LifesciencesIndiaAjanta PharmaIndiaAscend LaboratoriesIndiaCamber PharmaceuticalsIndiaDr. Reddy's LaboratoriesIndiaNivagen PharmaceuticalsRising Pharma HoldingsWestminster PharmaceuticalsXLCare Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store at 20° to 25°C (68° to 77°F), excursions permitted between 15° to 30°C (59° to 86°F). Protect from moisture and humidity.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- N06AX16 Venlafaxine
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 15 February 2019
- Identifiers
- RxCUI 808744, 808748, 808753 +1DailyMed set ID 45cb4c19-fbf4-4ff5-af6f-b25a31ebc1e1, dc989aa7-c4ab-4359-a971-523eb477ef9b, 22d4817c-1f19-4490-8a38-d8904f0374f7 +9NDC 75834-219, 47335-794, 27241-224 +9Application ANDA211323, ANDA091272, ANDA214691 +6
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
Packs from every labeler of this generic presentation.
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 100 tablet, extended release in 1 bottle | 70710-1352-1 | Zydus LifesciencesIndia | 1 September 2022 |
| 30 tablet, extended release in 1 bottle | 70710-1352-3 | Zydus LifesciencesIndia | 1 September 2022 |
| 90 tablet, extended release in 1 bottle | 70710-1352-9 | Zydus LifesciencesIndia | 1 September 2022 |
| 100 tablet, extended release in 1 bottle | 70771-1652-1 | Zydus LifesciencesIndia | 1 September 2022 |
| 30 tablet, extended release in 1 bottle | 70771-1652-3 | Zydus LifesciencesIndia | 1 September 2022 |
| 90 tablet, extended release in 1 bottle | 70771-1652-9 | Zydus LifesciencesIndia | 1 September 2022 |
| 30 tablet, extended release in 1 bottle | 27241-224-30 | Ajanta PharmaIndia | 12 April 2023 |
| 90 tablet, extended release in 1 bottle | 27241-224-90 | Ajanta PharmaIndia | 12 April 2023 |
| 30 tablet, extended release in 1 bottle | 67877-729-30 | Ascend LaboratoriesIndia | 11 June 2021 |
| 90 tablet, extended release in 1 bottle | 67877-729-90 | Ascend LaboratoriesIndia | 11 June 2021 |
| 30 tablet, extended release in 1 bottle | 31722-126-30 | Camber PharmaceuticalsIndia | 23 October 2020 |
| 90 tablet, extended release in 1 bottle | 31722-126-90 | Camber PharmaceuticalsIndia | 23 October 2020 |
| 30 tablet, extended release in 1 bottle | 43598-944-30 | Dr. Reddy's LaboratoriesIndia | 20 September 2021 |
| 90 tablet, extended release in 1 bottle | 43598-944-90 | Dr. Reddy's LaboratoriesIndia | 20 September 2021 |
| 100 tablet, extended release in 1 bottle | 47335-794-08 | Sun Pharmaceutical IndustriesIndia | 15 February 2019 |
| 500 tablet, extended release in 1 bottle | 47335-794-13 | Sun Pharmaceutical IndustriesIndia | 15 February 2019 |
| 90 tablet, extended release in 1 bottle | 47335-794-81 | Sun Pharmaceutical IndustriesIndia | 15 August 2019 |
| 30 tablet, extended release in 1 bottle | 47335-794-83 | Sun Pharmaceutical IndustriesIndia | 15 February 2019 |
| 100 tablet, extended release in 1 bottle | 47335-794-88 | Sun Pharmaceutical IndustriesIndia | 15 February 2019 |
| 5 blister pack in 1 box, unit-dose / 10 tablet, extended release in 1 blister pack | 47335-794-99 | Sun Pharmaceutical IndustriesIndia | 15 February 2019 |
| 1000 tablet, extended release in 1 bottle | 75834-219-00 | Nivagen Pharmaceuticals | 6 September 2019 |
| 30 tablet, extended release in 1 bottle | 75834-219-30 | Nivagen Pharmaceuticals | 6 September 2019 |
| 90 tablet, extended release in 1 bottle | 75834-219-90 | Nivagen Pharmaceuticals | 6 September 2019 |
| 30 tablet, extended release in 1 bottle | 64980-581-03 | Rising Pharma Holdings | 28 November 2022 |
| 90 tablet, extended release in 1 bottle | 64980-581-09 | Rising Pharma Holdings | 28 November 2022 |
| 30 tablet, extended release in 1 bottle | 72865-200-30 | XLCare Pharmaceuticals | 26 February 2021 |
| 90 tablet, extended release in 1 bottle | 72865-200-90 | XLCare Pharmaceuticals | 26 February 2021 |
| 30 tablet, extended release in 1 bottle | 68001-499-04 | BluePoint Laboratories | 30 April 2021 |
| 90 tablet, extended release in 1 bottle | 69367-418-09 | Westminster Pharmaceuticals | 18 November 2025 |
| 30 tablet, extended release in 1 bottle | 69367-418-30 | Westminster Pharmaceuticals | 18 November 2025 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 28 December 1993 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Venlafaxine
Clinical summary
Venlafaxine is a serotonin and norepinephrine reuptake inhibitor indicated in adults for the treatment of major Depressive Disorder (MDD), among other approved uses. It is available as extended-release capsules, tablets and extended-release tablets for oral use. MedsAcross supplies Venlafaxine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about VenlafaxineFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Effexor XR prescribing information (Viatris Specialty) · U.S. National Library of Medicine, DailyMed
Need Venlafaxine 225 mg extended-release tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.